Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 503 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizoaffective Disorders Clear all
Completed Not applicable Interventional

Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

NCT02192593
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computer CBT
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 21, 2026, 11:16 AM EDT
Not yet recruiting Not applicable Interventional

Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia

NCT07659938
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Frontal gamma coherence neurofeedback, Placebo Neurofeedback
Behavioral
Lead sponsor
BioSignal Solutions LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 21, 2026, 11:16 AM EDT
Not yet recruiting Not applicable Interventional

Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder

NCT07488156
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffective Disorder, Psychosis
Interventions
Educational sessions
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MicroRNAs as Biomarkers in First Episode Schizophrenia

NCT07703670
View directory record Official record
Conditions
Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Plasma NDE miRNA Sequencing, Whole Genome Sequencing
Diagnostic Test · Genetic
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCT00538642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Sulforaphane to Reduce Symptoms of Schizophrenia

NCT02810964
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sulforaphane Nutraceutical, Identical-appearing Placebo
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

NCT02421965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

NCT00237809
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D-serine, Cognitive Retraining (CRT), Placebo, Cognitive Retraining Placebo
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

Inpatient Evaluation of Adults With Schizophrenia

NCT00001247
View directory record Official record
Conditions
Schizophrenia
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

NCT03183609
View directory record Official record
Conditions
Schizophrenia, Gluten Sensitivity, Schizo Affective Disorder
Interventions
Gluten Flour in Protein Shake, Rice Flour in Protein Shake
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

NCT04856657
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions
Transcranial alternating current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional Results available

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

NCT00406718
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Med-eMonitor, PharmCAT, Treatment as Usual
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 21, 2026, 11:16 AM EDT
Not listed Not applicable Interventional

Comparing Cognitive Remediation Approaches for Schizophrenia

NCT04123223
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Games
Behavioral
Lead sponsor
Wesleyan University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Hartford, Connecticut • Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jul 21, 2026, 11:16 AM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCT00139906
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 21, 2026, 11:16 AM EDT
Withdrawn Not applicable Interventional

Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy

NCT05140135
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Recovery Oriented Cognitive Therapy (CT-R), Treatment as Usual
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

State Representation in Early Psychosis

NCT05273164
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 45 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 21, 2026, 11:16 AM EDT